You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

CLINICAL TRIALS PROFILE FOR ULTRAVIST 240


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ultravist 240

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00244140 ↗ Ultravist: Safety and Efficacy in Computed Tomography of Head and Body Completed Bayer Phase 3 2005-10-01 This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
NCT00876083 ↗ PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination Completed Bayer 2008-03-01 The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.
NCT00926562 ↗ A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients Completed Chinese PLA General Hospital Phase 4 2009-02-01 The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).
NCT01206257 ↗ The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) Completed Bayer 2010-08-01 This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity
NCT01255722 ↗ Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed Guerbet Phase 4 2010-11-01 The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability (quality and interpretability of images).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ultravist 240

Condition Name

Condition Name for Ultravist 240
Intervention Trials
Diagnostic Imaging 3
Kidney Failure, Chronic 2
Hypothyroidism 1
Nephropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ultravist 240
Intervention Trials
Renal Insufficiency 2
Kidney Failure, Chronic 2
Myocardial Ischemia 1
Coronary Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ultravist 240

Trials by Country

Trials by Country for Ultravist 240
Location Trials
China 23
United States 11
Korea, Republic of 3
Colombia 2
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ultravist 240
Location Trials
South Carolina 1
Pennsylvania 1
Ohio 1
New York 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ultravist 240

Clinical Trial Phase

Clinical Trial Phase for Ultravist 240
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ultravist 240
Clinical Trial Phase Trials
Completed 8
Unknown status 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ultravist 240

Sponsor Name

Sponsor Name for Ultravist 240
Sponsor Trials
Bayer 5
Yong Huo 1
Seoul National University Hospital 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ultravist 240
Sponsor Trials
Industry 7
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

ULTRAVIST 240: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction

ULTRAVIST 240, an iopromide-based nonionic, iodinated, low osmolar radiological contrast agent, has been a staple in medical imaging for decades. Introduced in Europe in 1985 and in the US in 1995, it is widely used for various intravascular and intravenous indications. Here, we delve into the clinical trials, market analysis, and future projections for ULTRAVIST 240.

Clinical Trials and Efficacy

Overview of Clinical Trials

ULTRAVIST 240 has been evaluated in numerous clinical trials to assess its safety and efficacy across different medical imaging procedures. These trials include:

  • Peripheral Venography: Two randomized, double-blind clinical trials involving 63 patients demonstrated excellent visualization ratings and radiologic diagnoses comparable to other low osmolar contrast agents like iohexol and ioversol[4][5].
  • Cerebral Arteriography: Trials involving patients with central nervous system diseases showed good to excellent visualization ratings in 99% of the patients, similar to iohexol and iopamidol[4].
  • Coronary Arteriography and Left Ventriculography: Studies in patients with altered coronary artery perfusion and ventricular function indicated effective visualization and diagnostic outcomes[4].
  • Contrast-Enhanced Computed Tomography (CECT): Trials for CECT of the head and body showed high visualization ratings and diagnostic accuracy, comparable to other contrast agents[4].

Safety Profile

The safety profile of ULTRAVIST 240 has been extensively studied. Common adverse reactions include headache, dysgeusia, abnormal vision, chest pain, and vasodilatation. More severe reactions, though rare, can include anaphylactoid shock, contrast-induced acute kidney injury, and cardiac complications[3][5].

Market Analysis

Global Presence

ULTRAVIST 240 is used in over 100 countries worldwide, reflecting its widespread acceptance and reliability in medical imaging. Its global presence is a testament to its efficacy and safety profile[2].

Market Share and Competition

In the market for radiological contrast agents, ULTRAVIST 240 competes with other low osmolar nonionic agents such as iohexol and iopamidol. However, its long history of use, proven safety, and wide range of indications have helped it maintain a significant market share. The market for contrast agents is growing due to the increasing demand for diagnostic imaging procedures, driven by an aging population and the rise in chronic diseases[2].

Economic Impact

The economic impact of ULTRAVIST 240 is substantial, given its widespread use. It contributes significantly to the revenue of its manufacturer, Bayer, and plays a crucial role in the healthcare sector by enabling accurate diagnoses and treatments. The cost-effectiveness of ULTRAVIST 240, balanced against its efficacy and safety, makes it a preferred choice for many healthcare providers[2].

Market Projections

Growing Demand for Diagnostic Imaging

The demand for diagnostic imaging procedures is expected to increase due to several factors, including an aging population, the rise in chronic diseases, and advancements in medical technology. This trend is likely to drive the demand for contrast agents like ULTRAVIST 240[2].

Technological Advancements

Advancements in imaging technologies, such as improved CT scanners and digital subtraction angiography, will continue to enhance the utility and effectiveness of ULTRAVIST 240. These advancements are expected to further solidify its position in the market[4].

Regulatory Environment

Regulatory approvals and guidelines play a crucial role in the market for pharmaceuticals and medical devices. ULTRAVIST 240 has a strong regulatory backing, having been approved for various indications. Continued compliance with regulatory standards will be essential for its continued market presence[3][4].

Key Indications and Usage

Intra-Arterial Use

ULTRAVIST 240 is indicated for intra-arterial digital subtraction angiography (IA-DSA), peripheral arteriography, and other vascular procedures. Its low viscosity and rapid iodine delivery rate make it particularly suitable for these applications[4].

Intravenous Use

It is also indicated for intravenous use in procedures such as contrast-enhanced computed tomography (CECT) of the head and body, excretory urography, and peripheral venography. The recommended dosages vary based on the specific procedure and patient population[1][4].

Patient Population and Dosage

Adult Dosage

For adults, the recommended dosage for cranial CT scans is 1.5 to 2.5 ml/kg body weight for ULTRAVIST 240. For other procedures like intravenous urography, the dosages are adjusted based on the patient's age and weight[1].

Pediatric Dosage

In pediatric patients, the dosages are tailored to the age and weight of the child. For example, neonates require higher doses relative to their body weight compared to older children and adults[1].

Safety and Side Effects

Common Adverse Reactions

Common side effects include headache, dysgeusia, abnormal vision, and vasodilatation. These reactions are generally mild and transient[3][5].

Severe Adverse Reactions

Severe reactions such as anaphylactoid shock, contrast-induced acute kidney injury, and cardiac complications are rare but can be life-threatening. Patients with a history of severe cutaneous adverse reactions should avoid ULTRAVIST 240[3].

Conclusion

ULTRAVIST 240 remains a vital tool in medical imaging due to its proven safety, efficacy, and wide range of indications. With a strong clinical trial background, significant global presence, and growing demand for diagnostic imaging, it is poised to continue playing a crucial role in the healthcare sector.

Key Takeaways

  • Proven Efficacy: ULTRAVIST 240 has been shown to be effective in various clinical trials across different medical imaging procedures.
  • Global Presence: It is used in over 100 countries, reflecting its widespread acceptance.
  • Safety Profile: While generally safe, it can cause common and rare adverse reactions, necessitating careful patient selection and monitoring.
  • Market Projections: The demand for ULTRAVIST 240 is expected to grow due to increasing diagnostic imaging needs and technological advancements.
  • Regulatory Compliance: Continued regulatory approvals are crucial for its market presence.

FAQs

What are the common indications for ULTRAVIST 240?

ULTRAVIST 240 is indicated for intra-arterial digital subtraction angiography, peripheral arteriography, contrast-enhanced computed tomography (CECT) of the head and body, excretory urography, and peripheral venography[4].

What are the common side effects of ULTRAVIST 240?

Common side effects include headache, dysgeusia, abnormal vision, and vasodilatation. Severe reactions such as anaphylactoid shock and contrast-induced acute kidney injury are rare but can occur[3][5].

How is ULTRAVIST 240 administered?

ULTRAVIST 240 can be administered intravenously or intra-arterially, with dosages varying based on the specific procedure and patient population[1][4].

Is ULTRAVIST 240 safe for pediatric patients?

Yes, ULTRAVIST 240 is safe for pediatric patients, but the dosages are adjusted based on the child's age and weight. Higher doses relative to body weight are often required for neonates and infants[1].

Can ULTRAVIST 240 be used in patients with renal impairment?

ULTRAVIST 240 can be used in patients with renal impairment, but caution is advised. The drug can be eliminated by hemodialysis, and patients with severe renal impairment may require dose adjustments[1].

What is the market outlook for ULTRAVIST 240?

The market outlook for ULTRAVIST 240 is positive, driven by the increasing demand for diagnostic imaging procedures and technological advancements in medical imaging[2].

Sources

  1. Bayer, ULTRAVIST 240 10 ml, 50 ml, [PDF].
  2. MXR Imaging, Ultravist 240 mgl/mL - Contrast for Injection X-Ray CT.
  3. FDA, ULTRAVIST (iopromide) Injection, for intravenous or intra-arterial use, [PDF].
  4. FDA, ULTRAVIST - accessdata.fda.gov, [PDF].
  5. RxList, Ultravist (Iopromide Injection): Side Effects, Uses, Dosage.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.